Paratesticular rhabdomyosarcoma

Abstract

Even though rhabdomyosarcoma is the most common soft tissue sarcoma in children, accounting for 5-10% of all malignant disease in children under 15 years of age, so few cases are seen in a single institution that only the combined efforts of multicentre prospective trials made it possible fro adequate treatment schedules to be devised. Thank to this cooperation, survival rates have increased dramatically in recent decades; risk factors have been identified and treatment can now be adapted accordingly. This is especially true for the paratesticular rhabdomyosarcoma (PTRM), which now has a good prognosis in all stages. The striking similarity of tumor behavior and metastatic pathways to those in germ-cell tumors in young male adults can provide us with more extensive data derived from a much larger group of patients. Recent data are gathered and evaluated in this review. Only in this way will it be possible to eliminate all treatment modalities known to be followed by severe sequelae, thus avoiding exposure of the patients to a therapy that carries more risks than the primary tumor itself.

Mixed‐type paratesticular rhabdomyosarcoma—A case report

“…The differences between paratesticular RMS and RMS in other sites include tumor position and subtype. Paratesticular RMS is easier to diagnose and treat early, because of the superficial and easier-to-access nature of the site [6]. Subtypes include alveolar, pleomorphic, embryonal, and mixed type [7].…”

Adult paratesticular tumours

“…The role of adjuvant chemotherapy in adult paratesticular sarcomas is not fully established. In children with paratesticular RMS adjuvant chemotherapy has had a dramatic effect on the overall survival [61,62]. Its use in adult paratesticular sarcoma has not yet been specifically addressed in a controlled study.…”

Primary Fibrosarcoma of the Testicle with Puzzling Post-surgery Presentation: Mimicking Recurrence

“…In this case, we advocate that the last suggestions is to do RPLND when there is radiological suspicion of LN residual after adjuvant chemotherapy. [20,21]. Its use in adult testicular sarcomas has not been yet specifically addressed in a controlled study [22].…”